ResMed Inc

ResMed Q2 2024 results: 3.7% revenue growth, $198m operating income, and new AI‑powered CPAP launches. 2024 EPS guidance $8‑$8.20 shows strong strategic focus and telehealth expansion.

Insider sales and option exercises at ResMed reveal a balance of liquidity and confidence, while modest institutional holdings underline the company’s steady long‑term growth outlook.

ResMed’s stable share price, strong 11 % revenue growth and 27 % operating margin show a resilient medical‑device leader poised to capitalize on AI‑driven RPM and value‑based care, making it a standout for investors and payers alike.

ResMed’s institutional and executive holdings reveal strong mid‑cap stability, while regulatory and competitive shifts hint at future growth risks and opportunities.

Explore ResMed’s latest executive changes, ETF inclusion, and analyst focus—key insights into its governance, market stance, and future outlook.

ResMed’s (RMD) share dip amid mixed analyst views reveals a healthcare‑tech stock with solid fundamentals, regulatory stability, and an innovative pipeline that could drive future upside.

ResMed reports a 18% revenue jump and EPS topping estimates, thanks to the new AirSense‑X mask, lean manufacturing cuts, and a fresh distribution hub.

ResMed Inc’s recent dip reflects a broader healthcare pullback, not company woes. Learn how sector trends, regulatory shifts, and digital health drive investor risk.

ResMed Inc. outpaces peers with consistent earnings beats and a growing digital health pipeline—discover why ASX investors trust its mid‑cap momentum.

ResMed’s AirSense 11 launch and new CSA algorithm boost its home‑care edge, but broadband, regulatory and cyber risks still threaten growth.